Kanvas Biosciences
Microbiome-based cancer therapeutics
About
Founded around microbiome science, Kanvas Biosciences develops novel spatial biology-based microbiome therapeutics targeting cancer. Their platform identifies beneficial bacteria to create immuno-oncology drugs like KAN-001 and KAN-003, aiming to enhance cancer treatment efficacy. Kanvas secures large funding rounds to advance preclinical development toward IND filings, partnering with major investors such as the Gates Foundation. The company operates a biotech therapeutic business model focusing on drug R&D, leveraging spatial biology to innovate treatments that improve patient outcomes in oncology.
Products
-
Kanvas Biosciences Platform
— A vertically-integrated technology stack powering live biotherapeutic drug development.
Customer sectors: biotech researchers, pharmaceutical developers
-
Live biotherapeutics pipeline
— Purpose-built therapeutics designed to modulate the microbiome in health and disease.
Customer sectors: clinical researchers, pharmaceutical developers
-
Spatial mapping discovery engine
— Provides detailed images of host-microbiome interactions to uncover complex biological connections.
Customer sectors: microbiome researchers, biotech scientists
-
Integrated in-house manufacturing
— Scalable and reproducible manufacturing translating discoveries into clinical-stage microbiome therapies.
Customer sectors: manufacturing specialists, clinical developers
Related Companies
Other startups in Biotech & Therapeutics
